CD4 News and Research

RSS

Altimmune announces positive preclinical results of intranasal COVID-19 vaccine candidate

Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.

13 Jul 2020

Dysfunctional T cells present at high levels in severe COVID-19

Now, a new study by researchers at Saarland University, Germany, and published on the preprint server medRxiv in July 2020 shows that there are higher levels of anti-SARS-CoV-2 T cells, which show significant alterations in the phenotype and function.

12 Jul 2020

Faulty immune response to SARS-CoV-2 one of the main causes of death

A new study published on the preprint server medRxiv in July 2020 describes the organ and tissue-specific spread of the virus causing the current COVID-19 pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

7 Jul 2020

Researchers find possible cause for SARS-CoV-2 reactive T cells in uninfected individuals

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) -2, leading to severe pneumonia, acute respiratory distress syndrome, and death in a sizable minority of cases. However, the most significant number are asymptomatic or have only mild infection from which they rapidly recover.

2 Jul 2020

Novavax SARS-CoV-2 vaccine candidate shows promise in animal models

A new study published on the preprint server bioRxiv in June 2020 shows that a candidate spike protein vaccine can induce neutralizing antibodies, antiviral T cell responses, and protection against infection.

2 Jul 2020

Important new findings on T cell immunity in COVID-19

Researchers at the Karolinska University Hospital and University Hospital of Wales report that people who have recovered from asymptomatic or mild cases of coronavirus disease 2019 (COVID-19) may have long-term T-cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Jul 2020

Novel vaccine that removes aged immune cells mitigates metabolic disorders in obese mice

Aging is a multifaceted process that affects our bodies in many ways. In a new study, researchers from Osaka University developed a novel vaccine that removes aged immune cells and then demonstrated an improvement of diabetes-associated metabolic derangements by vaccinating obese mice.

30 Jun 2020

Modified Vaccinia Ankara-based vaccine candidate for SARS-CoV-2

Now, a new study by researchers at Emory University, the University of Texas Medical Branch and the Ragon Institute and published on the preprint server bioRxiv in June 2020 reports the development of a promising new vaccine candidate that may rapidly and effectively induce the production of neutralizing antibodies against the spike protein of the virus.

30 Jun 2020

COVID-19 patients can rapidly generate virus-attacking T cells, shows study

Patients suffering from severe respiratory symptoms as a result of SARS-CoV-2 infection can rapidly generate virus-attacking T cells, and can increase this production over time, suggests a new study of T cells from 10 COVID-19 patients under intensive care treatment.

27 Jun 2020

Dysregulated inflammation in severe COVID-19

The continuing COVID-19 pandemic has so far caused 9.58 million cases and more than 488,000 deaths within just six months. The spectrum of disease is broad, from completely asymptomatic cases to critical illness ending in death. Now, a new paper by researchers from Yale University and published on the preprint server medRxiv* in June 2020 identifies an imbalance in immunological response that is linked to poor outcomes and early biomarkers that may help predict the course of the disease.

25 Jun 2020

Immune response variations across the COVID-19 spectrum

A new study published on the preprint server medRxiv in June 2020 describes differences in the adaptive and innate immune response in mild, moderate, and severe COVID-19. This may mean that permanent immune responses occur only in patients who recover from severe COVID-19.

25 Jun 2020

Exposure to SARS-CoV-2 can induce virus-specific T cell responses without seroconversion

A new study by researchers at Strasbourg University Hospital and published on the preprint server medRxiv* in June 2020 shows that COVID-19 antibody responses may sometimes be lacking following exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could lead to a significant underestimation of the number of infections and the number of individuals who have achieved immunity.

24 Jun 2020

SARS-CoV-2 induces broad T cell response in recovering patients

A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.

23 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

The role of brain cells in spreading HIV

Dr. Lena Al-Harthi speaks to News-Medical about her research into HIV treatment and the role of brain cells in spreading the HIV virus.

22 Jun 2020

Balanced B and T cell response required to control SARS-CoV-2

A new study by researchers in the Netherlands and published on the preprint server bioRxiv in June 2020 describes the differences in T and B cell responses seen in patients with severe COVID-19.

21 Jun 2020

Exposure to certain e-cig cartridges may cause fatal lung damage

Researchers at the University of Rochester Medical Center, New York, have shown that long-term exposure to certain electronic nicotine delivery systems (ENDS) may cause lung toxicity and injury among vapers.

16 Jun 2020

Females mount stronger T-cell response to SARS-CoV-2

A new study published on the preprint server medRxiv in June 2020 shows that immune cells, antibody levels, cytokine levels, and viral loads contribute to the sex difference seen in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Jun 2020

Researchers evaluate survivin expression in neuroendocrine tumors

Volume 11, Issue 23 of @Oncotarget reported that tissue microarrays of 132 patients were stained for survivin using immunohistochemistry and correlated with outcomes.

10 Jun 2020